Hypoxia-An overlooked trigger for thrombosis in COVID-19 and other critically ill patients.
作者信息
Thachil Jecko
机构信息
Department of Haematology, Manchester University Hospitals, Manchester, UK.
出版信息
J Thromb Haemost. 2020 Nov;18(11):3109-3110. doi: 10.1111/jth.15029.
Abstract
摘要
相似文献
1
Hypoxia-An overlooked trigger for thrombosis in COVID-19 and other critically ill patients.
J Thromb Haemost. 2020 Nov;18(11):3109-3110. doi: 10.1111/jth.15029.
2
Vascular Disease Patient Information Page: COVID-19-related thrombosis.
Vasc Med. 2020 Dec;25(6):604-607. doi: 10.1177/1358863X20963804. Epub 2020 Oct 12.
3
Major bleeding complications in critically ill patients with COVID-19 pneumonia.
J Thromb Thrombolysis. 2021 Jul;52(1):18-21. doi: 10.1007/s11239-021-02403-9. Epub 2021 Mar 1.
4
COVID-19 and thrombosis: searching for evidence.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):621-627. doi: 10.1182/hematology.2021000298.
5
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.
Thromb Res. 2020 Dec;196:432-434. doi: 10.1016/j.thromres.2020.09.039. Epub 2020 Oct 8.
6
Hypoxia and thrombosis in COVID-19: new considerations for air passengers.
J Travel Med. 2020 Dec 23;27(8). doi: 10.1093/jtm/taaa122.
7
Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221074353. doi: 10.1177/10760296221074353.
8
Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?
J Thromb Haemost. 2020 Nov;18(11):3106-3108. doi: 10.1111/jth.15021.
9
Stroke and Thromboprophylaxis in the Era of COVID-19.
J Stroke Cerebrovasc Dis. 2021 Jan;30(1):105392. doi: 10.1016/j.jstrokecerebrovasdis.2020.105392. Epub 2020 Oct 9.
10
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
Thromb Res. 2020 Dec;196:395-397. doi: 10.1016/j.thromres.2020.09.024. Epub 2020 Sep 17.
引用本文的文献
1
Venous Thromboembolism in Patients Hospitalized for COVID-19 in a Non-Intensive Care Unit.
J Clin Med. 2024 Jan 17;13(2):528. doi: 10.3390/jcm13020528.
2
Adhatoda vasica and Tinospora cordifolia extracts ameliorate clinical and molecular markers in mild COVID-19 patients: a randomized open-label three-armed study.
Eur J Med Res. 2023 Dec 4;28(1):556. doi: 10.1186/s40001-023-01507-7.
3
Imaging-Selected Host Responses in the Context of Infections.
J Infect Dis. 2023 Oct 3;228(Suppl 4):S302-S310. doi: 10.1093/infdis/jiad313.
4
Elevation of D-dimer levels are associated with early need for mechanical ventilation support in patients with COVID-19.
BMC Pulm Med. 2023 Aug 3;23(1):283. doi: 10.1186/s12890-023-02551-z.
5
Correlation between Hepatocyte Growth Factor (HGF) with D-Dimer and Interleukin-6 as Prognostic Markers of Coagulation and Inflammation in Long COVID-19 Survivors.
Curr Issues Mol Biol. 2023 Jul 8;45(7):5725-5740. doi: 10.3390/cimb45070361.
6
Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness.
Lancet Respir Med. 2023 Aug;11(8):726-738. doi: 10.1016/S2213-2600(23)00238-2. Epub 2023 Jul 17.
7
Thromboinflammation in long COVID-the elusive key to postinfection sequelae?
J Thromb Haemost. 2023 Aug;21(8):2020-2031. doi: 10.1016/j.jtha.2023.04.039. Epub 2023 May 11.
8
Venous thromboembolism in viral diseases: A comprehensive literature review.
Health Sci Rep. 2023 Feb 5;6(2):e1085. doi: 10.1002/hsr2.1085. eCollection 2023 Feb.
9
Coagulation Profile of COVID-19 Patients.
Life (Basel). 2022 Oct 20;12(10):1658. doi: 10.3390/life12101658.
10
Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation.
Front Cell Infect Microbiol. 2022 Apr 5;12:861703. doi: 10.3389/fcimb.2022.861703. eCollection 2022.
本文引用的文献
1
Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis.
J Thromb Haemost. 2020 Sep;18(9):2358-2363. doi: 10.1111/jth.14992. Epub 2020 Aug 27.
2
Features and incidence of thromboembolic disease: A comparative study between high and low altitude dwellers in Saudi Arabia.
Saudi J Biol Sci. 2020 Jun;27(6):1632-1636. doi: 10.1016/j.sjbs.2020.03.004. Epub 2020 Mar 12.
3
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
J Thromb Haemost. 2020 Jul;18(7):1548-1555. doi: 10.1111/jth.14872. Epub 2020 Jun 3.
4
Impact of respiratory symptoms and oxygen saturation on the risk of incident venous thromboembolism-the Tromsø study.
Res Pract Thromb Haemost. 2020 Jan 9;4(2):255-262. doi: 10.1002/rth2.12299. eCollection 2020 Feb.
5
Chronic Obstructive Pulmonary Disease and Risk of Mortality in Patients with Venous Thromboembolism-The Tromsø Study.
Thromb Haemost. 2020 Mar;120(3):477-483. doi: 10.1055/s-0039-3400744. Epub 2019 Dec 30.
6
The stimulation of thrombosis by hypoxia.
Thromb Res. 2019 Sep;181:77-83. doi: 10.1016/j.thromres.2019.07.013. Epub 2019 Jul 15.
7
Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases.
Future Med Chem. 2016 Apr;8(6):647-80. doi: 10.4155/fmc-2016-0012. Epub 2016 Apr 8.
8
Hypoxia, such as encountered at high altitude, promotes deep vein thrombosis in mice.
J Thromb Haemost. 2013 Sep;11(9):1773-5. doi: 10.1111/jth.12310.
9
Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
J Thromb Haemost. 2006 Mar;4(3):560-5. doi: 10.1111/j.1538-7836.2006.01792.x.
10
Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis.
Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2029-35. doi: 10.1161/01.atv.19.9.2029.
Zotero 插件